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Background: A higher prevalence of coeliac disease (CD) has been reported in patients with Williams-Beuren
syndrome (WBS), though coexistence with other autoimmune diseases has not been evaluated.
Objective: The aim of this study was to examine the prevalence of the more frequent autoimmune diseases and
organ- and non-organ specific autoantibodies in WBS.
Methods: We longitudinally analysed 46 WBS patients to evaluate the prevalence and co-occurrence of the major
autoantibodies and HLA typing for CD diagnosis. These data were compared with healthy age- and sex-matched
controls and Down (DS) and Turner (TS) syndrome patients.
Results: CD was diagnosed in one (2.2%) WBS patient; this differed significantly from DS and TS (respectively,
10.5% and 9.4%; P < 0.005) but not from healthy controls (0.6%; P = NS). However, no patients with WBS showed
anti-thyroid antibodies or other organ- and non-organ specific autoantibodies, which differed significantly from DS
(respectively, 10.5% and 7.0%; P < 0.005) and TS (respectively, 9.4% and 9.3%; P < 0.005) patients but not from
healthy controls (1.1% and 2.3%). The frequencies of CD-specific HLA-DQ heterodimers were not significantly higher
than controls, even though the WBS patients more frequently carried the DQA1*0505 allele (57% vs. 39%; P < 0.05).
Conclusions: CD may not be more frequent in patients with WBS. In fact, no evidence of a significantly higher
prevalence of other autoimmune diseases or positivity of the main organ and non-organ specific autoantibodies
was found in WBS, such as showed in the healthy controls and unlike by the patients with Turner or Down
syndrome. This should prompt us to better understand the occurrence of CD in WBS. Other studies or longer
follow-up might be useful to clarify this issue.Background
Williams-Beuren syndrome (WBS) is a well-recognised
disorder, with an incidence of approximately 1:10000 live
births, and is characterised by typical facial dysmorph-
isms, heart defects, short stature, and mental retardation
[1]. Over 90% of patients present a hemizygous deletion
of the elastin gene at 7q11.23 [2,3].
Although coeliac disease (CD) has been reported in
patients affected by different chromosomal disorders, in-
cluding Down syndrome (DS) and Turner syndrome
(TS) [4,5], this association has been reported only in* Correspondence: stefano.stagi@yahoo.it
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unless otherwise stated.sporadic patients with WBS [6-8]. Indeed, we are aware
of only two studies in which the prevalence of CD was
assessed in a representative series of WBS patients
[9,10], and the results were conflicting.
Furthermore, the coexistence and/or prevalence of
other autoimmune diseases and organ-specific autoanti-
bodies has not or has rarely been reported in these sub-
jects [11,12].
This study was performed to evaluate longitudinally
the prevalence of CD, autoimmune thyroid diseases, and
the more frequent organ- and non-organ specific auto-
antibodies, and to examine HLA typing for the diagnosis
of CD in a cohort of patients with WBS.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Between June 2003 and May 2011, the prevalence of CD,
autoimmune thyroid diseases, and the more frequent
organ- and non-organ specific autoantibodies was longi-
tudinally evaluated in 46 (21 from Tuscany, 23 from
south Italy-Campania, one from Albania, and one from
Chile) consecutive patients with WBS (30 females and
16 males; median age at the onset of the study was
15.4years [range: 4.2–35.3years]). The patients were re-
cruited by the Genetics and Molecular Medicine Unit at
Meyer Children’s University Hospital in Florence, Italy,
and by the Medical Genetics Unit at San Giuseppe Moscati
Hospital, in Avellino, Italy.
The diagnosis of WBS was achieved by the clinical
phenotype assessed by two experienced medical geneti-
cists and confirmed by fluorescent in situ hybridisation
(FISH) results for elastin deletion at 7q11.23. All of the
subjects with WBS in this study exhibited typical micro-
deletions of approximately 1.55 Mb. A minimum of 10
meta-phases was scored for deletion of the 7q11.23 re-
gion in each patient. In some cases, array CGH (44 K
array platform Agillent oligonucleotides with a reso-
lution of approximately 100 kb) was performed to ana-
lyse and precisely map the position of each deletion in
this region, and confirmed the minimal region of loss of
1.55 Mb.
Demographic data, family history of autoimmune disor-
ders up to second-degree relatives, drugs administered,
height, weight, and BMI were recorded for all patients, and
the following antibodies were evaluated: anti-thyroglobulin
(TgA), anti-thyroid peroxidase (TPOA), anti-TSH receptor
(TSHr), gliadin IgG/A (AGA), anti-endomysium (EmA),
and tissue-transglutaminase (tTG) IgA.
Additionally, insulin autoantibodies (IAA), glutamic
acid decarboxylase (GAD) and tyrosine phosphatase 2
(IA-2) antibodies, islet cell antibodies (ICA), anti-adrenal
cortex antibodies, anti-gastric parietal cell antibodies,
antinuclear antibodies (ANA), antismooth muscle anti-
bodies (ASMA), and antiphospholipid antibodies (APA)
were also evaluated for 21 patients. All autoantibodies
were evaluated annually or at least three times during
the study.
The study was approved by the Ethics Committees of
Anna Meyer Children’s University Hospital of Florence,
and San Giuseppe Moscati Hospital in Avellino. In-
formed written consent was obtained from the patients
and controls and/or their parents.
Familial autoimmunity
All patients and/or parents were interviewed about their
family history, to their second-degree relatives, of auto-
immune diseases. As previously described [13], the fol-
lowing autoimmune diseases were considered during the
family history: autoimmune thyroid diseases, rheumatoidarthritis and other rheumatologic disorders, CD, type 1
diabetes mellitus, vitiligo, alopecia, multiple sclerosis,
and inflammatory bowel disease.
Thyroid antibodies
Thyroid autoimmunity was evaluated by measuring
TPOA and TgA levels using fluorescence enzymatic im-
munoassays. The normal range was < 35 U/mL for TgA
and < 20 U/mL for TPOA.
TSHr autoantibodies were measured with THBIA (DiaSorin
spa, Vercelli, Italy) using a two-step radioreceptor assay;
TSHr was considered positive at values of > 9 U/L.
Coeliac disease
All patients underwent an evaluation of serum IgA, IgG/
A AGA, EmA, and tTG antibodies. Immunoglobulin (Ig)
concentrations were measured by enzyme-linked im-
munosorbent assay (ELISA) (IgA-human-ELISA quantita-
tion kit). IgA and IgG AGA were measured by ELISA as
well. EmA was assayed by a standard immunofluorescence
method using cryostat sections of monkey oesophagus.
Serum IgA tTG antibodies were assayed with a specific
ELISA. Diagnosis of CD was confirmed by performing a
small intestine biopsy if the specific autoantibody profile
was positive.
Other antibody assays
ICA was determined by indirect immunofluorescence on
cryosections of monkey pancreas using undiluted sera
(Inova Diagnostics, Inc., San Diego, CA, USA). GAD,
IAA and anti-IA-2 antibodies were measured by radio-
immunoassay (RIA) (RSR Ltd, Cardiff, UK).
Anti-adrenal cortex and anti-gastric parietal cell anti-
bodies were detected by indirect immunofluorescence
using monkey adrenal glands or gastric mucosa tissues as
the substrates (Inova Diagnostics, Inc., San Diego, CA,
USA). However, ANA was detected using an immuno-
fluorescent method with HEp-2 cell (Scimedx Corp.,
Denville, NJ, USA).
ASMA was detected by indirect immunofluorescence
using cryostat frozen sections of rat kidney (DiaSorin®
Deutschland GmbH - Dietzenbach, Germany). Finally,
IgG and IgM APA determination was performed using a
standardised ELISA (Diagnostica STAGO, Paris, France).
HLA typing
Blood (1–9 mL) was collected from all subjects, and
DNA for HLA-DQA1 and DQB1 genotyping was ex-
tracted. The PCR-amplified exon 2 amplicons were
gene-rated for low- to medium-resolution typing in a
combined single-stranded conformation polymorphism
(SSCP)/heteroduplex assay by a semi-automated electro-
phoresis and gel-staining method (Protrans HLA Celiac
Disease Domino System HLA CD Association kit, Nuclear
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(encoding the HLA-DQ2 heterodimer) and alleles DQA1*03
and DQB1*0302 (encoding the HLA-DQ8 heterodimer)
could be reliably characterised in both the homozygous
and heterozygous states.
Control groups
Data from the 46 WBS patients were compared with the
data from 176 healthy age- and sex-matched control
subjects (109 females and 67 males; median age of
15.2 years [range: 5.3–36.5 years]) admitted to the hos-
pital for minor surgery (i.e., adenotonsillectomy, phimo-
sis, dermoid cyst, and herniotomy). With regard to the
prevalence of HLA typing for the diagnosis of coeliac
disease, we compared the WBS patients with 343 healthy
adults blood donors (aged between 18–58 years; mean
age of 38.8 ± 8.5years).
To determine the prevalence of autoimmune thyroid dis-
eases and CD, the data were also compared to two groups
of patients age- and sex-matched that were affected by DS
(36 females and 21 males; median age of 15.1years [range:
4.9–23.4years]) and TS (32 females; median age of 16.2years
[range: 5.2–40.1years]).
Statistical analysis
Statistical analysis was performed using the SPSS statis-
tical package (SPSS Inc., Chicago, IL). Summaries of
continuous variables were given as the means ± SDs or
median and range, depending on whether the data were
normally distributed or not. When appropriate, the χ2
test or Fisher’s exact test was used to compare differ-
ences between cases and controls. Where appropriate,
Bonferroni’s correction for multiple comparisons was
applied. Inter-group comparisons for parameters were
conducted using analysis of variance (ANOVA) or using
repeated-measures analysis of covariance (ANCOVA), as
appropriate. Statistical tests were considered significant
when p < 0.05.
Results
The characteristics of controls and WBS, DS, and TS pa-
tients are shown in Table 1.
At the time of the end of the study, the mean follow-
up of the WBS patients was 7.4 ± 0.8 years (range 5.6 -
8.5 years). Autoantibodies were evaluated 6.2 ± 1.8 times
during the study, without differences among the deter-
mination of CD autoantibodies (7.4 ± 1.0 times), thyroid
autoantibodies (6.1 ± 1.8 times), and other autoanti-
bodies (6.6 ± 1.5 times).
Six (13%) WBS patients had a positive family history
for autoimmune diseases, three with autoimmune thy-
roid disease, two with rheumatoid arthritis, and one with
CD, though with no significant difference with respectto the controls (8.6%; P = NS). No patients showed an
IgA deficiency.
Regarding the prevalence of CD, only one WBS patient
(a male, 2.2%) was found to be positive for coeliac anti-
bodies; the diagnosis of CD was confirmed histologically.
However, this patient had a strong positivity for auto-
immune diseases in first relatives (autoimmune thyroid
disease in the mother and sister and CD in one maternal
cousin). Although the data for CD in WBS were not
significantly different from the healthy controls (0.6%;
P = NS), the data were significantly different from DS
(10.5%; P < 0.005) and TS (9.4%; P < 0.005).
In contrast, no patient with WBS tested positive for
TPOA, TgA, or TSHr, which was significantly different
from the DS (10.5%; P < 0.005) and TS (9.4%; P < 0.005)
patients, but not from the healthy controls (1.1%; P =NS).
Finally, the overall frequency of other organ- and non-
organ specific autoantibodies did not significantly differ
among WBS patients and the controls (0.0% vs. 2.3%),
but it was significantly different from DS and TS (7.0%
and 9.3%, respectively, P < 0.05).
Coeliac-specific HLA-DQ heterodimers were present in
20 patients (43%), though the frequency of each haplotype
were not significantly higher than those of the controls
(43%; P =NS). In particular, the DQ2 and DQ8 haplotypes
were positive in sixteen (34% vs. 33%; P =NS) and four pa-
tients (9% vs. 10%; P =NS), respectively.
Twenty-six patients (57%) tested negative for coeliac-specific
HLA-DQ heterodimers, but showed the DQA1*0505 allele.
This frequency was statistically significant with respect
to the controls (39%; P < 0.05).
Discussion
Our data show that patients with WBS do not develop
CD any more significantly than the general population
but less frequently than patients with DS and TS. In
addition, the WBS patients did not show a higher preva-
lence of anti-thyroid autoantibodies and other autoanti-
bodies than the healthy controls, and their prevalence
was significantly reduced in comparison to those with
TS and DS.
Therefore, our data appear to negate the utility of
assessing the main autoimmune diseases and organ- and
non-organ specific autoantibodies in WBS, as opposed
to other genetic disorders that are associated with a
higher prevalence of autoimmune diseases [14-16].
In a previous cross-sectional study [12] of patients
with WBS, and in agreement with other reports [17-19],
we found that these patients did not present positivity
for anti-thyroid autoantibodies. Nonetheless, other au-
thors have described rare cases of autoimmune thyroid
disease [11].
The data from the present longitudinal study confirm
our previous results [12]. However, our study did not
Table 1 Demographic data, familial occurrence of autoimmune diseases, organ- and non-organ-specific autoantibodies,
and coeliac disease prevalence in patients with Williams-Beuren syndrome, Down syndrome, Turner syndrome, and
healthy controls
WBS patients Down patients Turner patients Healthy controls
Subjects (n) 46 57 32 176
Males: females 16:30 21/36 32 67:109
Median age (yr) 15.4 15.1 16.2 15.2
Familial occurrence of autoimmune diseases 13% - - 8.6%
Confirmed coeliac disease 2.2% 10.5%*°° 9.4%*§§ 0.6%
Gliadin IgG autoantibodies 17.4%^^^ 19.3%°°° 15.6%§§§ 5.1%
Gliadin IgA autoantibodies 2.2% 12.3%**°° 12.5%**§§ 1.7%
Endomysium autoantibodies 2.2% 10.5%*°° 9.4%*§§ 0.6%
Tissue-transglutaminase autoantibodies 2.2% 12.3%**°° 9.4%*§§ 0.6%
Thyroid autoantibodies 0.0% 10.5%***°° 9.4%**§§ 1.1%
Thyroglobulin autoantibodies 0.0% 7.0%*° 6.2%*§ 1.1%
Thyroid peroxidase autoantibodies 0.0% 10.5%***°° 9.4%**§§ 0.6%
TSH receptor autoantibodies 0.0% 1.7% 0.0% 0.0%
Organ- and non-organ specific autoantibodies 0.0% 7.0%* 9.3%*§ 2.3%
Insulin autoantibodies 0.0% 0.0% 0.0% 0.0%
Glutamic acid decarboxylase autoantibodies 0.0% 1.75% 0.0% 0.0%
Tyrosine phosphatase 2 autoantibodies 0.0% 0.0% 0.0% 0,6%
Islet cell autoantibodies 0.0% 0.0% 0.0% 0.0%
Adrenal cortex autoantibodies 0.0% 0.0% 0.0% 0.0%
Gastric parietal cell autoantibodies 0.0% 1.75% 3.1% 0.0%
Antinuclear antibodies 0.0% 1.75% 6.2%§§§ 1.1%
Smooth muscle autoantibodies 0.0% 0.0% 0.0% 0.6%
Phospholipid autoantibodies 0.0% 1.75% 0.0% 0.0%
WBS, Williams-Beuren syndrome; *WBS vs. Down syndrome or Turner syndrome: *p < 0.05; **p < 0.005; ***p < 0.0005; ^WBS vs. controls: ^p < 0.05; ^^p < 0.005;
^^^p < 0.0005; °Down syndrome vs. controls: °p < 0.05; °°p < 0.005; °°°p < 0.0005; §Turner syndrome vs. controls: §p < 0.05; §§p < 0.005; §§§p < 0.001.
Stagi et al. BMC Medical Genetics 2014, 15:61 Page 4 of 6
http://www.biomedcentral.com/1471-2350/15/61find a significant prevalence of CD. For comparison,
Giannotti et al. [10] reported a prevalence of CD in 9.5%
of WBS patients, whereas Santer et al. [9] reported only
one (1.4%) WBS patient affected by CD in a series of 71
children undergoing specific screening. Our results, in
agreement with those of Santer et al. [9], may suggest
that the association of WS and CD is rare.
Nevertheless, the relatively small sample size may be a
limit of our study. However, compared to the two afore-
mentioned cross-sectional studies, our study represents
the first long longitudinal evaluation of autoimmunity in
the WBS patients, permitting to better capture the his-
tory of autoimmune disorders in these syndrome.
Despite the different sample size (71 patients in the
Santer et al. study, 63 patients in the Giannotti et al.
study, and 46 patients in the present study), the similar
median age and age range are common characteristics of
these three studies. Moreover, the two previous studies
not used anti-tissue transglutaminase antibodies, a useful
screening marker for CD. Also, both previous studiesdid not present a genetic study of HLA predisposition of
the patients.
We do not know because the study of Giannotti et al.
showed a very high frequency of CD with respect to our
data and the data of Santer et al. [9]. We may hypothesize
that other causes of small bowel biopsy lesions may be as-
sociated with diarrhea or malabsorption, even if only CD
responds to a gluten-free diet, such as infectious disorders,
deficiency of zinc, vitamin B12, and acid folic, drug-
induced small bowel injury [20].
Furthermore, WBS patients appear to not show a
more frequent prevalence of other autoimmune disor-
ders in addition to CD. This lack of correlation is clearly
different from other genetic syndromes related to auto-
immune disorders, such as TS and DS.
TS, one of the most common sex chromosome abnor-
malities [21] that is caused by the presence of only one
normally functioning X-chromosome, has a more fre-
quent prevalence (4.2–6.4%) of different autoimmune
diseases, such as autoimmune thyroid diseases and anti-
Stagi et al. BMC Medical Genetics 2014, 15:61 Page 5 of 6
http://www.biomedcentral.com/1471-2350/15/61thyroid antibodies with CD [16,22,23]. Other auto-
immune diseases described include inflammatory bowel
disease, insulin-dependent diabetes mellitus (IDDM),
Addison's disease, rheumatoid arthritis, myasthenia
gravis, vitiligo, alopecia, pernicious anaemia, and hypo-
parathyroidism [24].
There is also strong evidence for an association be-
tween DS and CD, with prevalence between 5% and 12%
[15]. Autoimmune thyroid diseases are the most fre-
quent autoimmune disorder coexisting with this syn-
drome, and most of the affected patients (varying from 3
to 28%) display detectable circulating thyroid-specific
autoantibodies [25]. An increased prevalence of type 1
diabetes mellitus over the general population has also
been described in these patients [25].
However, despite the data reported in a previous study
[10] regarding the higher prevalence of CD in WBS,
there are no available studies or protocols on the follow-
up of autoimmune disease in these patients, which is in
contrast to the situation for patients with TS and DS.
Among autoimmune disorders, an increased preva-
lence of CD and autoimmune thyroid diseases has been
found in patients with autoimmune thyroid disease, type
1 diabetes mellitus, autoimmune liver diseases, and in-
flammatory bowel disease [26]. Thus, a similar genetic
predisposition is common to many autoimmune dis-
eases, and the genes in the HLA complex are among the
strongest predisposing genetic factors [27].
Recent population screening studies have shown that
the prevalence of CD in Western countries approaches
1%. There is considerable genetic influence in CD; 90–
100% of affected individuals possess either the class II
HLA molecule DQ2 (DQA1*05/DQB1*02) and/or DQ8
(DQA1*0301/DQB1*0302) compared to 30–40% of the
general population [28,29].
Furthermore, whereas some authors have not provided
evidence of an association with CD and the ELN17
marker [30], our data suggest that WBS patients exhibit
the DQA1*0505 allele more frequently that controls
(56% vs. 39%; P < 0.05). The DQA1*0505 allele is similar
to the DQA1*0501 allele of the DQ2.5 haplotype [31].
However, some genetic studies have revealed that the
DQA1*0505:X/Y:DQB1*0202 gene products may explain
disease not linked to the haplotype that produces DQ8
and DQ2.5 [32].
Conclusion
In conclusion, no evidence of a significantly higher
prevalence of autoimmune diseases or positivity of the
main organ and non-organ specific autoantibodies was
found in subjects with WBS. This result appears to be
different with respect to other genetic syndromes (e.g.,
TS or DS), in which there is a major frequency of certain
autoimmune disorders. This should prompt us to betterunderstand the occurrence of CD in the WBS. Accord-
ingly, we suggest that routine examination of autoimmune
diseases should not be performed in the follow-up of
asymptomatic WBS patients. Other studies or longer
follow-up might be useful to clarify this issue.
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